SCHEMBL4293044

SCHEMBL4293044

N#Cc1ccccc1Oc1cnn(C2CCCCO2)c(=O)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.40
PIN1 Q13526 2/20 0.37
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
EZH2 Q15910 3/20 0.35
PDE9A O76083 1/20 0.35
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
SLC6A4 P31645 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KDM4E B2RXH2 1/20 0.34
DPP4 P27487 1/20 0.34
ATR Q13535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009089 0.84 LMNA (0.39) LMNAALDH1A1POLBHPGDHTT
SCHEMBL1009476 0.82 SCD (0.37) LMNAALDH1A1POLBHPGDHTT
SCHEMBL1009496 0.82 POLB (0.37) LMNAALDH1A1POLBHPGDHTT
SCHEMBL8740243 0.77 ALDH1A1 (0.43) LMNAALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL1009103 0.76 CYP4F2 (0.42) LMNAALDH1A1POLBHPGDHTT
SCHEMBL1008747 0.75 ALDH1A1 (0.41) LMNAALDH1A1POLBSMN1; SMN2
SCHEMBL1008524 0.73 ALDH1A1 (0.48) LMNAALDH1A1POLBHPGDHTT
SCHEMBL31104330 0.73 ALDH1A1 (0.39) LMNAALDH1A1POLBSMN1; SMN2ATR
SCHEMBL31104176 0.73 ALDH1A1 (0.39) LMNAALDH1A1POLBHTTSMN1; SMN2
SCHEMBL8237951 0.72 LMNA (0.40) LMNAALDH1A1POLBDPP4ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK SCN9A 3776/4885PIN1 4171/4885LMNA 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.